Table of Contents
Hepatitis Research and Treatment
Volume 2014, Article ID 860562, 11 pages
Research Article

MHC Class I Presented T Cell Epitopes as Potential Antigens for Therapeutic Vaccine against HBV Chronic Infection

1Immunotope, Inc., Doylestown, PA 18902, USA
2Baylor College of Medicine, Houston, TX 77030, USA
3Celldex Therapeutics, Hampton, NJ 08827, USA

Received 6 March 2014; Revised 9 April 2014; Accepted 18 April 2014; Published 26 May 2014

Academic Editor: Piero Luigi Almasio

Copyright © 2014 Joseph D. Comber et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Supplementary Material

Identification of MHC class I restricted peptides derived from HBV that did not meet cutoff criteria. The selection criteria for peptides are as follows: Charge 1: XCorr > 1.6; Charge 2: XCorr > 1.8; Charge 3: XCorr > 2.0. Peptides that have a XCorr lower than the cutoff value are considered “low confidence” “low abundance” peptides. These peptides have been previously described in [19].

  1. Supplementary Material